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Abstract.
Background: Lipid metabolism is altered in Alzheimer’s disease (AD); however, the relationship between AD risk factors
(age, APOE 4, and gender) and lipid metabolism is not well defined.
Objective: We investigated whether altered lipid metabolism associated with increased age, gender, and APOE status may
contribute to the development of AD by examining these risk factors in healthy controls and also clinically diagnosed AD
individuals.
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Methods: We performed plasma lipidomic profiling (582 lipid species) of the Australian Imaging, Biomarkers and Lifestyle
flagship study of aging cohort (AIBL) using liquid chromatography-mass spectrometry. Linear regression and interaction
analysis were used to explore the relationship between risk factors and plasma lipid species.
Results: We observed strong associations between plasma lipid species with gender and increasing age in cognitively normal
individuals. However, APOE 4 was relatively weakly associated with plasma lipid species. Interaction analysis identified
differential associations of sphingolipids and polyunsaturated fatty acid esterified lipid species with AD based on age and
gender, respectively. These data indicate that the risk associated with age, gender, and APOE 4 may, in part, be mediated
by changes in lipid metabolism.
Conclusion: This study extends our existing knowledge of the relationship between the lipidome and AD and highlights the
complexity of the relationships between lipid metabolism and AD at different ages and between men and women. This has
important implications for how we assess AD risk and also for potential therapeutic strategies involving modulation of lipid
metabolic pathways.
Keywords: Aging, Alzheimer’s disease, APOE 4, gender, lipid species
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neu-
rodegenerative disease associated with cognitive
impairment and is the most common form of demen-
tia. Increasing age is a major risk factor for AD [1] and
is driving the current increases in AD. Aging is also
associated with changes in lipid metabolism in brain
regions playing crucial roles in cognitive function [2,
3] which is reflected in the periphery [4].
The 4 allele of the apolipoprotein E gene (APOE)
is the strongest genetic risk factor for the sporadic
form of AD [5]. Individuals with two copies of the 4
allele have been reported to have a 14-fold increased
risk of developing both late onset and early onset spo-
radic AD. Given the role of apolipoprotein E protein
(ApoE) in lipid transport and metabolism, investigat-
ing the influences of different APOE alleles on lipid
metabolism is warranted.
Recent studies have indicated that gender may be a
potential risk factor for sporadic AD, and that females
are more susceptible to developing sporadic AD, even
after accounting for differences in longevity [6, 7].
In addition, gender may influence other risk factors,
such that men will be affected differently to women
[7]. We have previously reported on strong associ-
ations between many lipid species and gender [4,
8].
Lipids play an essential role in all mammalian
systems. Recent lipidomic studies have identified
multiple lipid classes and species associated with AD,
at both preclinical and clinical stages [9, 10]. These
studies have suggested that phospholipid, ceramide,
and sulfatide metabolism may be involved in AD
pathogenesis. Significant differences in ether lipids
and plasmalogens have also been reported in AD
studies which investigated both brain and serum
lipid species [11–13]. While the exact mechanism(s)
of AD pathogenesis are yet to be fully elucidated,
considerable evidence indicates the involvement of
aberrant lipid metabolism [11, 14]. In this study we
sought to better define the associations of AD and
its major risk factors (age, gender, and APOE) with
the plasma lipidome, and in particular, define how
age, gender, and APOE interact with the associations
between AD and the plasma lipidome.
MATERIALS AND METHODS
Participants
The current study utilized plasma samples and
data from the Australian Imaging, Biomarkers and
Lifestyle (AIBL) flagship study of aging, which
recruited 1,112 individuals over the age of 60 years
into a longitudinal study (follow-up at 18-month
intervals) for AD. In this paper, cross-sectional data
to the latest available time point were used to max-
imize the number of participants available because
at the later time points there were more dropouts.
Time points were used as a covariate to remove any
association based on time point.
The AIBL study was approved by the institutional
ethics committees of Austin Health, St Vincent’s
Health, Hollywood Private Hospital and Edith Cowan
University. Written informed consent was given
by all volunteers before participating in the study.
Individuals with a history of non-AD dementia,
schizophrenia, bipolar disorder, significant current
depression, Parkinson’s disease, cancer (other than
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basal cell skin carcinoma) within the last two years,
symptomatic stroke, uncontrolled diabetes, or current
regular alcohol use exceeding two standard drinks per
day for women or four per day for men, were excluded
from the study [15]. Details of the selection criteria
can be found in Ellis et al. [15].
Blood collection and storage, APOE genotyping
All study volunteers fasted for a minimum of
10 h overnight prior to blood collection. Blood draw
was carried out using standard serologic techniques
and fractionated as described previously by Ellis et
al. [15] followed by storage at –80◦C for research.
Within the current study, lipid metabolites were mea-
sured in the plasma.
Apolipoprotein E (APOE) genotype was deter-
mined following extraction and purification of
genomic DNA from 0.5 ml whole blood. Each sam-
ple was genotyped for the presence of the three APOE
variants (2, 3, and 4) based on TaqMan SNP geno-
typing assays for rs7412 (C 904973) and rs429358 (C
3084793) as per the manufacturer’s instructions (AB
Applied Biosystems by Life Technologies, Victoria,
Australia).
Lipid extraction and lipidomic analysis
Lipid species were extracted from 10L plasma,
with the addition of an internal standard mix
(Supplementary Table 3), using the single phase
butanol/methanol extraction method as described
previously [16]. 10L aliquots of plasma were mixed
with 100L of 1-butanol:methanol (1:1 v/v) with
5 mM ammonium formate containing an internal
standard mix. The mixture was vortexed for 10 s
and sonicated for 60 min in a sonic water bath
at 25◦C and then centrifuged (16,000 × g, 10 min,
20◦C). The supernatant was transferred into a 0.2 mL
glass insert with Teflon insert cap for analysis by
ultra-performance liquid chromatography electro-
spray ionization tandem mass spectrometry.
The solvent system consisted of solvent A) 50%
H2O/30% acetonitrile/20% isopropanol (v/v/v) con-
taining 10 mM ammonium formate) and solvent B)
1% H2O/9% acetonitrile/90% isopropanol (v/v/v)
containing 10 mM ammonium formate. The follow-
ing mass spectrometer conditions were used; gas
temperature, 150◦C, gas flow rate 17 L/min, nebu-
lizer 20 psi, Sheath gas temperature 200◦C, capillary
voltage 3500 V and sheath gas flow 10 L/min.
Plasma quality control (PQC) samples consisting
of a pooled set of 6 healthy individuals were incor-
porated into the analysis at 1 PQC per 18 plasma
samples. Technical quality control samples (TQC)
consisted of PQC extracts which were pooled and
split into individual vials to provide a measure of
technical variation from the mass spectrometer only.
These were included at a ratio of 1 TQC per 18 plasma
samples. TQCs were monitored for changes in peak
area, width and retention time to determine the perfor-
mance of the LC-MS/MS analysis and the PQCs were
subsequently used to align for differential responses
across the analytical batches.
Characterization of phospholipid isomers
The fatty acid composition of phospholipids was
characterized by either collision induced dissociation
(CID) in negative ionization mode, for neutral or neg-
atively charged species, or by CID of lithium adducts
in positive ionization mode for positively charged
species and subsequently used to infer structural com-
position on our chromatography. Fragmentation in
negative mode enabled the identification of frag-
ment ions corresponding to the fatty acyl species.
Fragmentation of the lithium adducts in positive
ion mode enabled identification of fragment ions
corresponding to the loss of the fatty acyl con-
stituents. Characterization of the phospholipid fatty
acids was performed on whole lipid extracts of
PQC samples. For the analysis of lithium adducts
of phosphatidylcholine, alkylphosphatidylcholine,
alkenylphosphatidylcholine, and sphingomyelin, the
10 mM ammonium formate in the extraction buffer
and running solvents were substituted with 200M
lithium acetate, which provided the ability to monitor
for lithium adducts for additional structural informa-
tion.
Liquid chromatography mass spectrometry
Analysis of plasma extracts was performed on
an Agilent 6490 QQQ mass spectrometer with an
Agilent 1290 series HPLC system and a ZORBAX
eclipse plus C18 column (2.1 × 100 mm, 1.8m,
Agilent) with the thermostat set at 60◦C [8]. Mass
spectrometry analysis was performed in positive ion
mode, with dynamic scheduled multiple reaction
monitoring (MRM). Mass spectrometry settings and
MRM transitions for each lipid class are shown in
Supplementary Table 3. Detailed description of the
method is presented in Huynh et al. [8].
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Data integration, batch alignment, and statistical
analysis
Data integration was carried out using Agilent
Mass Hunter version 8.0. Each batch was aligned
using its PQC samples and log transformed prior
to statistical analysis. A total of 582 lipid species
were used for analysis. Statistical analysis was carried
out using R version 3.4.1 for linear and logisti-
cal modelling with covariates. For linear regression,
data was not mean centered and standard deviation
scaled to allow the coefficients to be back transformed
into percentage change for interpretation. For logis-
tic regression, data was mean centered and standard
deviation scaled. Sporadic missing values (∼5%)
were observed for (BMI, total cholesterol, HDL-C,
and triglycerides) in the AIBL clinical database. To
avoid exclusion of entire samples due to such missing
values, we utilized multiple imputations by chained
equations [17] to estimate these parameters utiliz-
ing other related clinical variables (age, sex, BMI,
HDL-C, total cholesterol, and triglycerides). Every
time we imputed, we used a subset of these vari-
ables (age, sex, BMI, HDL-C, total cholesterol, and
triglycerides).
Associations between risk factors (age, gender, and
APOE 4) and lipid species (as outcomes) were deter-
mined using linear regression of the latest available
samples from individuals who did not develop MCI
or AD. These analyses were adjusted for the other
risk factors (age, gender, and APOE 4) as appro-
priate, in addition to BMI, total cholesterol, HDL-C,
triglycerides, site of collection and time point, statin
treatment, and omega 3 supplementation as indi-
cated. -coefficients and 95% confidence intervals
were converted to percentage change (percent-
age change = (10∧−coefficient–1) × 100). Covariates
involving statin treatment or DHA intake (fish oil,
krill oil) were treated as binary variables. Correction
for multiple comparison was by the method of Ben-
jamini and Hochberg. For interaction analysis with
age, gender, or APOE 4, binary variables were used,
where male = 1, age >75 = 1 and one or more copies
of 4 = 1.
Interaction analyses (2-df) tested each lipid
metabolite individually on a binary risk factor (+addi-
tional covariates as stated) with AD as the outcome.
For each binary risk factor (Age >75, Sex, APOE 4)
two models were used with the assignment of the
risk factor switched between 0 and 1 for each model.
This provided associations (coefficient, CI, and sig-
nificance) between each lipid and AD for both risk
groups (i.e., male and female) to aid in interpretation
of the interaction.
Naming convention of lipid species
The lipid naming convention used here follows
the guidelines established by the Lipid Maps Con-
sortium and the shorthand notation established by
Liebisch et al. [18, 19]. Glycerophospholipids typi-
cally contain two fatty acid chains and in the absence
of detailed characterization are expressed as the sum
composition of carbon atoms and double bonds (i.e.,
the phosphatidylcholine species, PC(38:6). However,
where an acyl chain composition has been determined
the naming convention indicates this (i.e., PC(38:6)
is renamed to PC(16:0 22:6), where the sn1 and sn2
positions are unknown or to PC(16:0/22:6) where the
sn positions are known). This is also extended into
other lipid classes and subclasses.
Species separated chromatographically but incom-
pletely characterized were labelled with an (a) or (b),
for example the phosphatidylcholine plasmalogen
species, PC(P-17:0/20:4) (a) and (b) where (a) and (b)
represent the elution order. Triglyceride species are
measured using a single neutral loss experiment and
are represented as their sum composition with their
neutral loss experiment (i.e., TG(56:2) [NL-18:2]).
RESULTS
Associations of plasma lipid species with risk
factors for Alzheimer’s disease
We examined the associations between lipid
species and risk factors for AD (age, gender, and
APOE 4 status) utilizing the most recent time-point
sample of non-MCI/AD individuals (controls). Par-
ticipant characteristics (at the time of sample) are
shown in Supplementary Table 1.
Age was associated with 195 lipid species (cor-
rected for multiple comparisons) after adjusting for
gender, BMI, site of collection, and collection time-
point. When further adjustment for clinical lipids
(total cholesterol, HDL-C, and triglycerides) was per-
formed, age was associated with 153 lipid species. A
summary of these associations is presented in Fig. 1,
and further details can be found in Supplementary
Table 2. Acylcarnitine species showed the strongest
association with increasing age (Fig. 1, Supple-
mentary Table 2). Significant negative associations
were also observed with ethanolamine plasmalogens
(Fig. 1B, Supplementary Table 2).
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Fig. 1. Associations between Alzheimer’s disease risk factors and plasma lipid species. Linear regression analyses of risk factors against
plasma lipid species were performed adjusting for covariates as indicated. The most recent available sample of each healthy control individual
were used (n = 696). A, B) Associations between plasma lipids and aging. A) Lipids with a p-value less than 3.01 × 10–6 (top 20) are
highlighted in blue. B) Ethanolamine plasmalogens, PE(P), with p < 0.05 are highlighted in light blue. C, D) Associations between lipids and
gender. C) Lipids with a p-value less than 3.25 × 10–13 (top 20) are highlighted in red. D) Glycerophospholipids esterified with a 22:6 fatty
acid with p < 0.05 (DHA, docosahexaenoic acid) are highlighted in orange. E, F) Associations between lipids and APOE 4 status. E) Lipids
with a p-value less than 1.13 × 10–2 (top 20) are highlighted in green. F) Ethanolamine plasmalogens, PE(P), with p < 0.05 are highlighted
in light green.
There were 385 lipid species associated with gen-
der (299 species when covariates included clinical
lipids). Sphingolipids with a d18:2 base exhib-
ited a stronger association than other lipid species
with a particularly strong association noted for the
sphingomyelin, SM(d18:2/14:0) (Fig. 1C). Nearly
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all glycerophospholipids esterified with docosahex-
aenoic acid were positively associated with being
female (Fig. 1D, Supplementary Table 2).
By comparison the associations between plasma
lipid species and the APOE 4 allele were rela-
tively weak. There were 31 lipid species associated
with APOE 4 prior to correction for multiple com-
parisons (45 species when the analysis was also
adjusted for clinical lipids). In general, the APOE 4
allele was associated positively with lysophosphati-
dylethanolamine and acylcarnitine species, but neg-
atively associated with phosphatidylethanolamine
ether lipids including plasmalogens, PE(O) and
PE(P), along with dihydroceramides, Cer(d18:0)
species, and alkyldiacylglycerols, TG(O), (Fig. 1E,
F, Supplementary Table 2). However, these were
not significant after correction for multiple compar-
isons.
As APOE 2 is considered to be protective against
the risk of developing AD relative to APOE 4,
we examined the lipid associations with 4 rela-
tive to 2, excluding 3 homozygotes. In total 127
species have an uncorrected p-value less than 0.05,
39 lipid species were associated with APOE 4 after
correction for multiple comparisons (Supplemen-
tary Table 2). In addition to the species described
above, which typically showed stronger associations,
several dihydroceramides and ceramides were neg-
atively associated with 4 (relative to 2), while
some cholesteryl ester species showed positive
associations, other cholesteryl species showed neg-
ative associations. The phosphatidylethanolamine
and lysophosphatidylethanolamine species were pos-
itively associated with 4 relative to 2.
Common lipid associations with Alzheimer’s
disease and its risk factors
We examined the data for associations between
lipid species and clinically diagnosed AD using logis-
tic regression adjusting for the same covariates as for
the risk factor analyses (Supplementary Table 2).
Comparing associations between lipid species and
age in the control group, with lipid species and clin-
ically diagnosed AD, 108 lipid species associated in
the same direction with an uncorrected p-value less
than 0.05 (i.e., increased with aging and increased in
AD). From these, 47 lipid species that were negatively
associated with AD were found to decrease with
increasing age; whereas the other 61 lipid species
positively associated with AD were found to increase
with increasing age. There are also four lipid species,
which associated opposingly between lipid species
and age in the control group with lipid species and
clinically diagnosed AD (Fig. 2 and Supplementary
Table 4). In general, increasing age and AD were both
found to be associated with decreases in ether lipids
containing polyunsaturated fatty acids, higher levels
of certain sphingolipid species (dependent on their
acyl composition), increases in odd and branched
fatty acids, decreases in ubiquinone and increases in
species of phosphatidylethanolamine and triacylglyc-
erol.
When examining the associations between lipid
species and APOE 4 allele status, and between lipid
species and AD, there were 18 species that associated
with both AD and APOE status. As the associa-
tions with APOE status were performed on control
samples only and the associations with AD were per-
formed adjusting for APOE status, these common
lipid associations are independently associated with
both outcomes. All of these species were negatively
associated (Fig. 2 and Supplementary Table 4). Out
of the 18 species associated with both APOE status
and AD, 14 were ether lipid species.
There were 13 lipid species associated with aging,
APOE 4, and AD in a similar manner (i.e., all nega-
tively associated). These species were predominantly
ether lipids (Fig. 2 and Supplementary Table 4). We
also performed these analyses adjusting for DHA
supplementation and statin use, but this resulted in
little difference to the associations (Supplementary
Table 5).
Comparing associations between lipid species and
gender in the control group, with lipid species and
clinically diagnosed AD, 75 lipid species associated
in the same direction with an uncorrected p-value less
than 0.05 while 44 lipid species were associated in the
opposite direction. Out of the 44 opposing species, 14
were sphingolipid species (Fig. 2 and Supplementary
Table 4).
When examining the associations between lipid
species and gender and between lipid species and
age, 114 lipid species were associated with gender
and age. 56 of the 114 lipid species were positively
associated, 26 of the 114 lipid species were negatively
associated, and the remaining 32 were associated
in opposing direction. 15 of the positively associ-
ated lipid species were sphingolipid species and 16
of the positively associated lipid species were phos-
phatidylethanolamine species. 9 of the 32 opposing
lipids were acylcarnitine species (Fig. 2 and Supple-
mentary Table 4).
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Fig. 2. Common associations between plasma lipid species with Alzheimer’s disease, aging, gender, and APOE 4 status. Lipids with
uncorrected p-values < 0.05 were used for this analysis. Associations were adjusted for covariates as outlined in Supplementary Table 4.
Associations of risk factors with plasma lipid species were performed on n = 696 controls. Associations of AD with plasma lipid species
were performed on n = 696 controls and n = 268 AD. A) Common associations of plasma lipid species with age, APOE 4, and AD. B)
Common associations of plasma lipid species with age, gender, and AD.
There were 53 lipid species associated with gen-
der, aging, and AD. Of these 53 lipid species,
25 were positively associated, with 15 of the 53
lipid species negatively associated and the remain-
ing 13 species were opposingly associated. 10
of the positively associated lipid species were
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Fig. 3. Interactions of age and gender with the associations between plasma lipid species and Alzheimer’s disease. Regression analysis with
an interaction term identified lipid species that associated with AD differently in relation to age and gender. Analysis were adjusted for age,
gender, BMI, total cholesterol, HDL cholesterol, triglycerides, site, and time-point of collection (n = 696 controls, 268 AD). A) Logistic
regression examining lipid species associations with AD with an age interaction (stratified above and below 75 years of age). B) Logistic
regression examining lipid species associations with AD with a gender interaction.
phosphatidylethanolamine species (Fig. 2 and Sup-
plementary Table 4).
Interaction of risk factors with the associations
of lipid species with Alzheimer’s disease
We next tested whether lipid species were associ-
ated differently with AD; depending on age, gender,
and APOE 4 status. Interaction with age was tested
by defining a binary cut-off at age 75, and interac-
tions with APOE 4 were tested using a binary cut
for one or more 4 alleles. Characteristics of this
split are shown in Supplementary Table 1. There
were 451 individuals (n = 390/61 controls/AD) 75
or younger and 513 individuals (n = 306/207 con-
trols/AD) older than 75 at sample collection. Males
and females had similar proportions of control and
AD subjects (288/109 versus 408/159 control/AD
for males and females respectively) whereas within
the 4+ve group, there were a much higher propor-
tion of AD subjects (non 4, 523/99 control/AD and
4, 173/169 control/AD). We identified 107 lipid
species, which demonstrated significant interactions
with age (Fig. 3A, Supplementary Table 6). Multiple
sphingolipid species showed a significant interaction
with age; where species that were negatively associ-
ated with AD showed a stronger association in the
younger age group (Fig. 3). Our results indicate that
individuals that develop AD earlier present with a
larger change in their sphingolipidome, particularly
long acyl chain species thought to be synthesized by
ceramide synthase 2. There was also an overall neg-
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ative association with dihydroceramide seen in the
younger group.
In both age groups, we observed negative associ-
ations between AD and DHA-esterified ether lipids.
However, additional species were negatively associ-
ated with AD in the younger age group, including
linoleic acid (18:2) and arachidonic acid (20:4) con-
taining species. In contrast, lipid species containing
particular omega-6 fatty acids such as adrenic acid,
22:4 n-6, and docosapentaenoic acid 22:5 n-6 showed
stronger positive associations with AD in the older
age group (Fig. 3 and Supplementary Table 5).
We next examined whether gender significantly
interacted with the association between lipid species
and AD. We found 71 lipid species with a signif-
icant gender interaction. The strongest interactions
with gender were observed in species esterified with
polyunsaturated fatty acids from both the omega-3
and omega-6 pathways. The association with AD for
the ethanolamine plasmalogen, PE(P-16:0/20:5) had
an odds ratio of 0.63 (95% CI 0.50–0.78, corrected p-
value = 7.39 × 10–4, Supplementary Table 2). When
examined with an interaction term (p = 1.18 × 10–2)
males were not significantly associated, with an
odds ratio = 0.83 (95% CI 0.61–1.14), whereas
females showed a stronger association, with an odds
ratio = 0.49 (95% CI 0.36–0.66, corrected p-value
1.47 × 10–4) (Fig. 3 and Supplementary Table 6).
This same effect was seen for all species with a signif-
icant interaction, as it was found that the association
between lipid species and AD was markedly weaker
in males than in females (Fig. 3 and Supplementary
Table 6).
We next explored why polyunsaturated fatty acid-
esterified phospholipids associated differently with
AD, dependent on gender. Initial analysis highlighted
differences in DHA containing lipid species between
healthy control males and females (Fig. 1D). It was
interesting to note that DHA lipid species are differ-
ent between cognitively normal males and females
(1D) even after additional adjustments for omega-3
supplementation and statin use (Fig. 4A), however
these gender-specific differences was not observed
in individuals with AD (Fig. 4C). Plotting unad-
justed concentrations of ether lipids (22:6)-esterified
highlighted the differences in concentrations of
DHA ether lipids between cognitively normal men
and women (Fig. 4B). The associations of gen-
der with DHA-esterified ether lipids (Fig. 1D)
were lost in the AD sub-cohort and adjustment
for omega-3 supplementation had no further effect
(Fig. 4C, D).
We observed very little interaction between APOE
alleles and the lipid associations with AD. Only 10
lipid species had a significant interaction value. In
general lipid associations were stronger for those
without an 4 allele (Supplementary Table 6).
DISCUSSION
In this study we have exploited the comprehensive
lipidomic analysis of the AIBL cohort to examine in
greater detail the relationship between plasma lipid
species, AD risk factors (age, gender, and the APOE
4 allele) and clinically diagnosed AD. We further
explored the interaction of these risk factors with the
associations between the lipidome and AD.
Ether lipids are associated with APOE 4, aging,
and Alzheimer’s disease
On examination of two major risk factors for
AD, namely age and possession of APOE 4 alle-
les, we observed common associations within the
ether lipid classes, as 10 of the 13 lipid species
that were independently negatively associated with
aging, the 4 allele, and AD, were ether lipids.
Our observations are consistent with previous stud-
ies reporting lipid abnormalities in AD pathogenesis
[20]. In particular a decrease in total phosphatidy-
lethanolamine plasmalogen and a decrease in some
phosphatidylcholine-plasmalogen species have been
reported [9] in AD brains. The potential mecha-
nisms of ether lipids in mediating AD risk are of
great interest. It has been shown that the APP
secretases are tightly associated with cell mem-
branes and specifically with lipid rafts [21, 22].
In particular, the formation of A is dependent on
the - and -secretases which are both expressed
and regulated by lipid rafts; whereas in contrast,
-secretase, the enzyme that is essential for non-
amyloidogenic proteolysis of APP, is expressed
and exerts its activity via non-lipid raft membrane
domains [23]. Ether lipids have been found to asso-
ciate with lipid rafts [24], and Rothhaar et al. [25]
identified a strong relationship between this sub-
group of ether lipids—the plasmalogens (the major
brain phospholipids)—and -secretase activity. It
was found that the addition of phosphatidylcholine
plasmalogens to AD brain tissue caused a reduc-
tion in -secretase activity [25]. Work by Grimm
et al. identified dysregulation of ether lipid biosyn-
thetic enzymes in the presence of A in patients
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Fig. 4. Associations of DHA containing lipid species with gender in control and Alzheimer’s disease groups. A) Linear regression of lipid
species against gender, adjusting for clinical covariates, omega-3 supplementation and statin use using most recent samples of cognitively
normal controls (n = 696). B) Concentrations of total PE(O) and PE(P) species esterified with a 22:6 fatty acid in cognitively normal males
(n = 288) and females (n = 408), and in AD males (n = 109) and females (n = 159). p-values were obtained from a Dunn’s test after Kruskal-
Wallis analysis. Black lines represent the median with 95% confidence intervals. C, D) Linear regression adjusting for clinical covariates using
most recent samples of AD individuals (n = 268). C) No adjustment for omega-3 supplementation. D) Adjusted for omega-3 supplementation.
with AD [26]. In particular, alkyl-dihydroxyacetone
phosphate-synthase (AGPS), a rate-limiting enzyme
in plasmalogen synthesis, has been shown to be
regulated by APP processing. Increased A lev-
els, which are observed in AD, led to peroxisomal
dysfunction and reduced AGPS protein stability.
This causes a reduction in AGPS protein levels
and eventually a reduction in plasmalogen synthesis
[26].
Another link between plasmalogens and AD comes
from the finding that A peptides increase phos-
pholipase A2 activity, which is responsible for the
degradation of plasmalogens [27, 28]. This may
lead to a vicious cycle whereby A peptides reduce
plasmalogen levels and the reduced plasmalogen lev-
els directly increase -secretase activity, leading to
a higher production of A peptides. Furthermore,
oxidative stress is known to be an early event of
AD pathogenesis which results in membrane damage,
including the loss of plasmalogens, thereby exacer-
bating oxidative stress as they act as antioxidants
[29], although not all studies agree on the antioxidant
activity of plasmalogens [20].
Since ether lipids have been proposed to have func-
tional roles in several aspects of metabolism that
relate to the onset and progression of AD, this raises
the possibility that ether lipids may be protective
for AD and that the decreased levels observed with
increasing age and the APOE 4 allele may medi-
ate the increased risk associated with these factors.
However, further studies are required to validate these
hypotheses.
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Interactions between age and gender and plasma
lipid levels, and their association with
Alzheimer’s disease
Individuals that develop AD at a younger age are
likely to exhibit more severe pathology and perform
worse in cognitive tests [30, 31]. Several ceramide
species, thought to be regulated by ceramide synthase
2, showed an association with AD; these ceramide
species also showed a significant interaction with age,
with the younger group (under 75 years) showing a
stronger association between ceramide species and
AD than the older group. Thus, the dysregulation of
the sphingolipidome appears to be associated with
earlier onset and a more severe form of the disease.
Whether such changes in sphingolipid metabolism
facilitate the pathogenesis of AD remains to be deter-
mined, as does the specific role of ceramide synthase
2 in the dysregulation of these lipid species.
Almost half of the lipid species measured in this
study differed between males and females even after
adjustment for multiple anthropometric measures and
clinical lipids. We observed a dramatic shift in the
effect size of the associations between lipid species
and AD when using gender as an interaction term. In
general, odds ratios for females were stronger (lower
for negative associations, higher for positive associa-
tions) compared to males. This was particularly true
for lipid species containing polyunsaturated fatty acid
species, which were typically higher in females.
Several studies have indicated differences in MCI
and AD prevalence between genders [32, 33], where
females appear to have a higher risk [34]. Gender
differences in mortality and survival rates in rela-
tion to AD have also been reported [35]. Potential
biological mechanisms for these differences in risk
may relate to differences in lipid metabolism. One
early study examining dietary intake of omega-3 fatty
acids and incident AD identified a significant inter-
action with gender [36], where the protective effect
of dietary omega-3 fatty acids was predominately
seen in women. It has previously been reported that
conversion of DHA precursors to DHA is higher in
women compared to men, resulting in higher circu-
lating DHA levels [37–39].
Our results indicate higher DHA levels in cogni-
tively normal females, but this gender difference is
not observed in the AD subset, as both males and
females show lower levels of lipid species esterified
with omega-3 fatty acids relative to the control group.
This contributes to the significant interaction between
gender and the association of these lipid species with
AD. Thus, in females, the higher levels of omega-3
esterified lipid species appear not to be protective,
but rather show a greater decrease in AD compared
to the decrease observed in males (i.e., resulting in no
difference in absolute concentrations between males
and females with AD). This would support the con-
cept that omega-3 fatty acids are not in themselves
protective against AD, and may explain the failure
of intervention trials with omega-3 supplementation.
Rather, we observe lower levels of omega-3 esteri-
fied lipid species in AD, which may represent reverse
causation, in other words lower levels of omega-3
esterified lipid species may simply be part of the
pathology, not a cause but the fact that the levels
decrease more markedly in females may argue that
the pathology is more aggressive in the latter. Further
studies are needed to elucidate the mechanism behind
these changes and differences in lipid levels.
The method employed in this current study enabled
us to perform an in-depth examination of 582
lipid species and investigations into the relationship
of age, gender, risk factors, and AD. Limitations
acknowledged within the current study include the
cross-sectional design of the study, and therefore
further studies are required to validate the current
findings longitudinally in an independent cohort.
While this study is relatively large in comparison
to many lipidomic and AD studies in the litera-
ture, statistical analyses to estimate interaction effects
typically require larger studies to identify associa-
tions of similar effect size. This resulted in limited
powered to identify all potential interaction effects,
in particular disease associations derived from dif-
ferent APOE alleles. A second limitation, inherent
to the design of the AIBL study, is the cohort
enrichment for memory complainers and those diag-
nosed with a memory problem. Further validation
should include a population cohort. Further, due to
the size of the cohort examined in this study, we
employed a high throughput method, which did not
allow the complete separation of all isomeric species,
which may have limited our ability to detect some
associations.
Conclusion
We find in this study that ether lipids and plasmalo-
gens associate with all risk factors of AD and with AD
itself. While APOE 4 was only weakly associated
with the plasma lipidome, the inclusion of APOE 2
showed stronger associations suggesting the protec-
tive effect of APOE 2 may be more tightly coupled
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to lipid metabolism than the risk associated with the
APOE 4 allele. Both age and sex showed signifi-
cant interactions with the associations of the lipidome
with AD, although these were largely different. The
interaction of age was predominantly with sphin-
golipids and ether lipids, while sex showed a strong
interaction with the associations between omega-3
esterified lipid species and AD. This study extends
our existing knowledge of the relationship between
the lipidome and AD and highlights the complexity of
the relationships between lipid metabolism and AD
at different ages and between men and women. This
has important implications for how we assess AD risk
and also for potential therapeutic strategies involving
modulation of lipid metabolic pathways. With further
validation, lipid species have a potential to contribute
as prognostic indicators of AD.
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